Serum Testosterone Level on Angiographic Complexity of Coronary Lesions in Premature Ischemic Egyptian Males

Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexMale
AgeUp to 45
SponsorSohag University

About this trial

This study aims to investigate the association between serum testosterone levels and the angiographic complexity of coronary artery lesions in male patients under 45 years of age presenting with premature ischemic heart disease.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Male patients aged <45 years.

Diagnosed with premature ischemic heart disease.

Undergoing elective coronary angiography for suspected coronary artery disease (CAD) .

Disqualifiers

History of acute coronary syndrome within the preceding 3 months.

Prior diagnosis of hypogonadism or history of testosterone replacement therapy or anabolic steroid use.

Active neoplasm or history of chemotherapy.

Known hepatic cirrhosis, chronic kidney disease, or end-stage renal disease.

Trial population

This prospective study will be conducted at Sohag University Hospitals after approval from the institutional ethical committee.

Trial design

Design model

Cohort

Time perspective

Prospective

Treatments tested in this trial

  • Coronary Angiography

    Other intervention

    All angiographic procedures will be performed. Coronary artery disease will be defined as \>70% stenosis in at least one major epicardial artery or \>50% the left main coronary artery.

  • Syntax Score

    Other intervention

    The angiographic complexity of coronary artery disease (CAD) will be assessed using the SYNTAX score.

Treatment groups

50 Participants
are divided into 2 treatment groups
Group A: Significant coronary artery disease (CAD) group2 interventions
Group B: Non-significant coronary artery disease (CAD) group2 interventions

Trial outcomes

Primary outcomes

1

Serum testosterone level

Serum testosterone level will be measured.

Time frame
Immediately after angiography (Up to 1 hour)

Secondary outcomes

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.